Decoy Therapeutics (NASDAQ:DCOY) Posts Quarterly Earnings Results

Decoy Therapeutics (NASDAQ:DCOY) released its earnings results on Tuesday. The company reported $43.10 earnings per share for the quarter, FiscalAI reports.

Decoy Therapeutics Stock Up 1.5%

Decoy Therapeutics stock opened at $6.42 on Thursday. The firm has a market capitalization of $3.40 million, a price-to-earnings ratio of -0.02 and a beta of 0.37. The business’s fifty day moving average is $8.25. Decoy Therapeutics has a 52-week low of $5.94 and a 52-week high of $415.80.

Wall Street Analyst Weigh In

A number of brokerages have commented on DCOY. LADENBURG THALM/SH SH began coverage on Decoy Therapeutics in a research report on Friday, January 23rd. They issued a “buy” rating and a $30.00 price objective for the company. Wall Street Zen upgraded Decoy Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 21st. Finally, Weiss Ratings started coverage on Decoy Therapeutics in a research report on Thursday, January 22nd. They issued a “sell (e)” rating for the company. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Decoy Therapeutics presently has an average rating of “Hold” and a consensus target price of $30.00.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.